Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Core Insights - Nurix Therapeutics is advancing a pipeline of innovative targeted protein degrader drugs in oncology and inflammation and immunology, each with best-in-class potential [2] Group 1: Lead Program Update - The call will focus on an important update regarding the lead program in chronic lymphocytic leukemia (CLL), specifically the drug bexobrutideg (NX-5948 or Bexdeg) [2] - Key discussions will include pivotal clinical development plans and new data supporting differentiation and dose selection for registrational trials of Bexdeg [2] Group 2: Partnered Pipeline Insights - New preclinical data from the partnered inflammation and immunology pipeline will be shared, specifically from the STAT6 and IRAK4 programs [3] - The STAT6 program is partnered with Sanofi, marking the first public disclosure of preclinical data profiling [3]